1 day Ago By Defense World Staff
CytomX Therapeutics, Inc. ( NASDAQ:CTMX – Get Free Report ) saw a large decline in short interest in the month of August. As of August 31st, there was short interest totalling 7,150,000 shares, a decline of 9.
1% from the August 15th total of 7,870,000 shares. Based on an average daily trading volume, of 1,100,000 shares, the short-interest ratio is presently 6.5 days.
CytomX Therapeutics Stock Performance CytomX Therapeutics stock traded down $0.02 during trading on Wednesday, reaching $1.19.
851,194 shares of the company’s stock were exchanged, compared to its average volume of 2,912,922. The company’s 50-day moving average is $1.28 and its two-hundred day moving average is $1.
74. CytomX Therapeutics has a 52-week low of $1.04 and a 52-week high of $5.
85. The firm has a market cap of $92.72 million, a price-to-earnings ratio of 5.
95 and a beta of 1.03. CytomX Therapeutics ( NASDAQ:CTMX – Get Free Report ) last announced its quarterly earnings results on Thursday, August 8th.
The biotechnology company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.
01). CytomX Therapeutics had a negative return on equity of 27.44% and a net margin of 9.
27%. The business had revenue of $25.12 million for the quarter, compared to analysts’ expectations of $21.
79 million. During the same period last year, the company posted ($0.02) earnings per share.
Analysts anticipate that CytomX Therapeutics will post -0.2 EPS for the current year. Institutional Trading of CytomX Therapeutics Analyst Ratings Changes Several brokerages have recently issued reports on CTMX.
Piper Sandler raised shares of CytomX Therapeutics from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $2.25 to $3.50 in a research note on Tuesday, May 28th.
HC Wainwright reissued a “neutral” rating on shares of CytomX Therapeutics in a research note on Friday, September 13th. Finally, StockNews.com cut shares of CytomX Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, June 17th.
Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, CytomX Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $5.
77. Read Our Latest Stock Report on CytomX Therapeutics About CytomX Therapeutics ( Get Free Report ) CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.
Featured Articles Five stocks we like better than CytomX Therapeutics Investing in Construction Stocks How Much Can You Make in Stocks in One Month? What Are Dividend Challengers? This Is the Top Large-Cap Stock Insiders Are Buying ESG Stocks, What Investors Should Know Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..
